Skip to content
AGI Future Foundation PBC

W3 Series 27 · Intended / Planned

Genomic DAO

A planned DAO for genomic data stewardship — consent, privacy, and shared benefit for the most personal data there is.

What this series isGet involved

The AGI Future Foundation is a California Nonprofit Public Benefit Corporation, Entity No. B20260196664, Articles filed 2026-04-24, EIN assigned 2026-05-07. No IRS 501(c)(3) determination letter is in the Foundation's files, so the Foundation does not claim tax-exempt status and does not claim that donations to it are tax-deductible. Nothing on this page is an offer of securities, an investment solicitation, or legal, tax, or financial advice.

What this series is

Genomic DAO is W3 Series 27. The April 2026 internal W3 series list names “W3 LLC-Genomic DAO — Series 27” and gives no further description, so everything about its scope on this page is a planned focus drawn from what the name implies, labelled as planned. What the name implies is a serious and narrow lane: the governance of genomic data — who consents to its use, under what terms, for what purposes, and with what benefit returning to the people the data came from.

Genomic data is unlike most data a series might handle, and the planned focus has to start from that fact. A genome identifies a person and their relatives; it cannot be changed if it leaks; and its interpretation changes as science advances, so consent given for one use may not cover a use invented five years later. A DAO in this lane would therefore be, first and foremost, a consent and stewardship body, not a data marketplace. Its job, as planned, would be to hold the line on three questions: did the person whose data this is agree to this specific use, can that agreement be withdrawn, and does the benefit of the use flow back to the people and communities who contributed? Any design that cannot answer those three questions in plain language would fail the Foundation's public-benefit standard before it started.

The companion series Genome.Blockchain (Series 28) is the natural counterpart: where Genomic DAO would govern the decisions, Genome.Blockchain would hold the verifiable record of them. That division — decisions in one series, records in another — is a planned separation of powers, not an operating arrangement, and it would need a written agreement between the two series defining exactly what each one holds, who can see what, and what happens when they disagree. The neighbouring life-sciences series — BioDAO.blockchain (Series 18), Curable.Blockchain (Series 17), and Diagnostic.X (Series 3) — mark the wider field this series would work inside: biology, cures, and diagnostics. Genomic DAO's distinct contribution, as planned, is not doing genomics itself but governing how genomic data is used by others.

Because the stakes are high, the bar for this series is higher than for most. Before any data is handled, the series would need counsel on the applicable law in every jurisdiction it touches, a written consent architecture with granular, revocable permissions, a data-minimisation rule (hold the least data needed, for the shortest time needed), and a named human accountable for breaches and for saying no to uses that fail the consent test. It would also need a clear statement that it does not diagnose, treat, or advise individuals on the basis of their genome: screening support and research governance are the planned lane, and clinical claims are outside it. None of these protections exists today. They are requirements the series would have to satisfy to earn the right to operate, and this page lists them so that a future reviewer can check whether they were met — not to imply that they already have been.

Validation for Genomic DAO would look different from validation for a consumer product. It would not be measured first in users or volume, but in trust: would people with genomic data to share, and researchers who need it, accept this DAO as a fair steward? That is a question that can only be answered by talking to both sides — patient communities, research institutions, and privacy experts — and by publishing the governance rules for public comment before any data flows. A DAO that launches its rules and its data handling at the same time has the order backwards. The planned sequence is rules first, published and reviewed; data second, with consent; and benefit-sharing terms third, agreed before value is created rather than negotiated after it.

Metaverse connection

Genomic DAO has no anchored metaverse fabric yet. No coordinates, no fabric URL, no world, and no RP1 status exist for this series, and none is claimed here. Zero worlds are live on RP1. The six anchored worlds in the Foundation's network belong to SmartCiti.X, Cognition.X, Locator.X, Biota.blockchain (unnumbered), Empathic.X, and Diagnostic.X — none of them is this series. A genomic data steward would need a metaverse presence only if there were a specific purpose for one — for example, a place where stewards and contributors meet and review proposals — and even then a world would be a meeting place, not a place where genomic data itself is stored or shown. What would be needed first is a defined fabric and a stated purpose; neither exists today.

That is the complete, verified statement of this series' metaverse position. There is nothing further to add, because there is nothing further on record: no fabric, no coordinates, no world, no contract, no token, no members, and no votes. If any of that changes, this page should be updated with the dated evidence — a fabric address, a world identifier, a transaction record — rather than with a new claim. Until then, the absence is the fact, and this page reports it.

Visit in VR

This series has no flagship world in the worlds-3d lobby and no live world on RP1 — zero worlds are live on RP1. What it does have is a listing: the worlds-3d lobby’s searchable index of 544 WorldForge worlds carries a curated entry for this series under the slug s27-genomic-dao. That entry is an index listing, not a playable world, and it should not be read as one.

To look around the Foundation’s VR spaces, start at the Foundation VR tour, or browse the full 544-world index at the worlds-3d lobby and search for the slug above. The seven playable flagship worlds in the lobby are the AGI Corp Hub, Biota.blockchain, Cognition.X, Diagnostic.X, Empathic.X, Locator.X, and the SmartCiti.X Holodeck — none of them is this series.

In the agi-corp-worlds registry, this series has a series directory (worlds/s27-genomic-dao/) but its founder focus is unset: the focus sheet records every focus as null, so this series is listed there as awaiting a founder focus, with no spec, zones, or agents written for it. A world for this series cannot be built honestly until a steward writes that focus down.

What exists today vs what is planned

What exists today

One line on an internal list: the April 2026 W3 series list names this series and its number. The Foundation itself is verified as filed (see the status note above). That is the complete inventory. There is no formed series entity, no designation document, no operating agreement, no Steward Council, no bank account, no product, no users, no revenue, no partners, no customers, no sites, and no timeline. This page does not present a plan as an achievement, and it does not fill the empty inventory with plausible-sounding detail.

What is planned

A DAO-managed series in the intended W3 network, operating day to day through agents within human-set limits, with a human Steward Council deciding, signing, and moving funds, and with the Foundation as mission gate under written agreements. Before any of that can happen, the series needs a written statement of purpose, a designated legal form, counsel's review, a named steward, and a first stage-gate decision. Each of those is a human decision with a dated record. None has been made yet.

The gap between the two cards above is the work. It is normal for a planned series to have that gap; what would not be normal is pretending it does not exist. Readers, reviewers, and potential stewards should judge this series by what is on record, and should ask for the dated record behind any future claim that the gap has closed.

How it fits

This series sits in the third tier of the Foundation's intended three-tier architecture. The apex tier is governance: the AGI Future Foundation itself, a California nonprofit public benefit corporation, holding the Fiduciary Shield and the mission standard. The middle tier is the commercial engine: W3 LLC, an intended Wyoming series LLC, which would house the individual series as legally segregated sub-series with isolated assets and liability. The third tier is the series themselves — this page among them — each a specialised, agent-operated DAO within its own lane. The tier structure is the plan; only the apex tier is verified as filed. The middle tier and this series are intended, not formed.

Related series (planned relationships only; no agreements exist):

The closest planned relationship is with Genome.Blockchain (Series 28): governance decisions here, verifiable records there. BioDAO.blockchain (Series 18) and Curable.Blockchain (Series 17) are the wider life-sciences neighbours. No agreements, shared systems, or shared data exist between any of them today.

Governance: DAO-managed day to day, humans decide

Under the Foundation's intended venture-studio model, each W3 series is DAO-managed in its day-to-day operation: agents operate the series within limits set by humans, and a human Steward Council decides. That division is deliberate and non-negotiable in the model. Agents prepare proposals, analysis, drafts, and coordination; agents never sign legal documents, never move funds, never hire or fire, never offer securities, and never enact doctrine or charters. Humans execute. Every material decision — forming the series, opening a bank account, signing a partnership, spending money, or taking on an obligation — requires a named human's decision and signature.

The Foundation sits above the W3 series as a mission gate, not as an owner in the ordinary commercial sense: a California nonprofit cannot be owned or controlled by a for-profit head, and the Foundation's board must remain independent. Control in the intended model runs through written mission agreements and standards the series agree to, with counsel to design the exact structure. The Foundation's public-benefit purpose — safe, equitable, and socially beneficial AI — is the standard every series is meant to be measured against, and the Windfall Clause framework is planned to apply across the W3 series: a legal pre-commitment, hardwired before profits, under which returns above a threshold (to be set by counsel, expressed in the pitch framework as a percentage of global GDP) would flow to humanity through global public goods. The threshold, measurement, recipient, and enforceability are all blank for counsel today, and no series page states them as settled terms.

Governance of a series, once designated, would also need a written operating agreement, a named Steward Council, a compliance calendar, and separate accounts and records per series. None of that exists for this series yet, because the series itself does not exist yet as a legal entity. The governance described on this page is the intended model, not a description of a operating body. Anyone reading this page who wants to help shape that governance should contact the Foundation (see below) rather than assuming any of it is already in force.

Open questions this series must answer before it can proceed

  1. What consent architecture would the DAO use, and can consent be granular and revocable in practice, not only in principle?
  2. Which jurisdictions' genomic and privacy law apply, and has counsel confirmed the design before any data is handled?
  3. How would benefit flow back to the people and communities whose data is used, and who decides what counts as a fair share?

These are not rhetorical questions. Each one needs a written answer, approved by a named human, before the series passes its first stage gate. If you can help answer one of them, the contact below is the route.

Proposed projects — for DAO review

These are proposals for the series DAO team to review. None is approved, funded, staffed, or scheduled.

The April 2026 internal W3 series list names W3 LLC-Genomic DAO, Series 27, and gives no further description, so everything about its scope on this page is a planned focus drawn from what the name implies. The name implies a serious and narrow lane: the governance of genomic data, who consents to its use, under what terms, for what purposes, and with what benefit returning to the people the data came from. The proposals below are generic to that name-implied planned focus.

Scope paper

A one-page written statement of what genomic data stewardship means for this DAO: consent, privacy, and shared benefit for the most personal data there is. The paper would be approved by stewards before any data work begins. No such paper exists today.

What success would look like: A scope paper exists that the stewards have approved, stating what genomic stewardship covers here.

Reviewing team: the Genomic DAO DAO

Status: PROPOSED — pending DAO team review

No funding, partner, or timeline yet.

Consent model draft

A draft model for consent to genomic data use: what a person consents to, how consent is given and withdrawn, and how withdrawal is honoured. The draft would be approved before any genomic data is handled. No such model exists today.

What success would look like: A consent model exists describing giving, recording, and withdrawing consent to genomic data use.

Reviewing team: the Genomic DAO DAO

Status: PROPOSED — pending DAO team review

No funding, partner, or timeline yet.

Benefit-sharing principles

Written principles for benefit returning to the people genomic data came from: what benefit means, who decides, and how it is shared. The principles would be agreed before any data is used. No such principles exist today.

What success would look like: A principles draft exists that the stewards have approved, covering benefit-sharing with data contributors.

Reviewing team: the Genomic DAO DAO

Status: PROPOSED — pending DAO team review

No funding, partner, or timeline yet.

Privacy and security standard

A standard for the most personal data there is: how genomic data is protected, who may access it, and what happens if protection fails. The standard would be written before any genomic data is held. No such standard exists today.

What success would look like: A privacy and security standard exists covering protection, access, and failure response.

Reviewing team: the Genomic DAO DAO

Status: PROPOSED — pending DAO team review

No funding, partner, or timeline yet.

S27 and S28 mapping note

A written note keeping the S27 and S28 mapping flagged as ambiguous: the genomic-site repo is the genomic-go-platform landing, and whether it belongs to S27 Genomic DAO, S28 Genome.Blockchain, or both is not settled. The note would keep the ambiguity flagged rather than resolving it by guessing. No such note exists today.

What success would look like: A mapping note exists that both DAO teams have read, keeping the S27 and S28 ambiguity flagged.

Reviewing team: the Genomic DAO DAO

Status: PROPOSED — pending DAO team review

No funding, partner, or timeline yet.

Code and repositories

  • genomic-site — Landing stub only, no substantive code.
  • genomic-go-platform — Fork of an outside platform; 651-line README claims 35 agent swarms, but only about six source files and one test file, last committed 2026-03-01. README scale claims are the fork's, not verified built capacity.

Shared registry entries (the same for every series in the intended network — these are registry and tooling files, not a product for this series):

  • agi-corp-worlds — the fabric-and-agent registry. This series has a series directory there (worlds/s27-genomic-dao/), but its founder focus is unset: the focus sheet records every focus as null, so the series is listed as awaiting a founder focus and no spec, zones, or agents have been written for it. Its spec metaprompt is marked not ready for the same reason.
  • Generated agent prompts and advisor contracts in the same repo (agents/prompts/ and agents/advisors/) — one generated prompt file and one scripted advisor contract per world, covering the series worlds. The three advisors per world are Host, Steward Liaison, and Alignment; advisors are scripted guides, not AI, and get no prompt by contract. The prompts are deterministic stubs held to a ten-point eval (umbrella present, every human-reserved action listed and marked Held for the Steward Council, every forbidden action listed, source cited, zone named, no personal data, under 6,000 characters) — and no model has run any of them.
  • DAO management pattern in the same repo (agents/dao.mjs) — one DAO team per world, seated in the eight agent roles the charter assigns to agents (research synthesis, task routing, proposal generation, operational coordination, progress tracking, monitoring, collaborator scouting, grant drafting). Proposals move draft → under review → enacted or declined, with steward transitions requiring a 2-of-3 steward quorum; no treasury is held and treasury.transfer is refused to everyone.

Note: the S27 and S28 mapping is ambiguous. This is kept flagged here. Do not resolve it by guessing.

The biology in depth

Abstract illustration of a double-helix ribbon rising from a dark field with glowing data points
AI-generated illustration

Genomics is the reading and interpretation of genomes: the complete DNA of an organism, and how variation in that DNA relates to traits, disease risk, and response to treatment. The field runs from sequencing — producing the raw letters — through analysis — finding variants, genes, and pathways — to interpretation, where a finding has to be weighed for evidence, uncertainty, and clinical meaning. Proteomics, the study of the proteins a genome produces, and drug development, where a genomic finding becomes a therapeutic target, sit alongside it. Genomic data is identifiable by nature: a genome identifies its owner, so consent, access control, and the right to withdraw are central to any honest genomic programme, and they have to be designed before data is collected, not after.

Longevity appears in this field as a research direction: the genomic study of ageing, and whether variation in ageing-related genes points to interventions. The platform repository below lists longevity among its claimed swarm categories. That is a claimed category in a README, not verified built capacity, and this page claims no longevity outcome, therapy, or timeline. Any future longevity work would be presented as research, with its evidence and its limits stated together.

What is verified for this series is one substantive-but-thin repository and one landing stub, checked live 2026-11-06/07. genomic-go-platform is a fork of an outside platform, AGI-Corporation/genomic-go-platform, missed by the 2026-11-05 review of 56 repositories. Its 651-line README describes a large platform — 35 agent swarms, about 75 agents per swarm, AlphaFold3, molecular dynamics, compound generation with ADMET validation, DeSci virtual labs, and swarm categories including drug discovery, longevity, fertility, and regenerative medicine — but the code is far thinner than the README: about six source files, one test file, and seven documents, last committed 2026-03-01, eight months stale at the time of the check, with no verified deployment, demo, or run status in the README. Its scale claims are the fork's claims, not verified built capacity. genomic-site is a six-line landing stub only, with no substantive code behind the name. The subdomain genomic.agifuturefoundation.org was unreachable by curl in the check and is not linked here as live.

The split with S28 Genome.Blockchain is unresolved: the two artifacts above are cited here under S27, and they are not assigned to S28. No trial, result, partnership, or timeline is verified for Genomic DAO, and none is claimed here.

All verified BioDAO tools are listed together, with charts, on the BioDAO tools page.

Get involved / contact

If you can help define, steward, or review this series — as a domain expert, a prospective steward, a researcher, or a reviewer — contact the Foundation at [email protected]. Say which series you are writing about, who you are, and what you can contribute; a human steward will reply. Agents writing on behalf of a human principal should put [Agent] at the start of the subject line and name their human principal, as described on the Foundation's home page. Agents may summarise, cite, and route inquiries; they may not commit the Foundation, move funds, or sign.

This is not an investment solicitation. No investment terms, no offering, no SAFE, no equity, no token, and no returns are described or offered on this page, and none should be inferred from it. Nothing on this page is legal, tax, or financial advice. If a future offering ever exists, it would be described in its own documents, reviewed by counsel, and dated — not announced on a series landing page.

Other series in this group: Mypet.AI · Lyka DAO · Genomic DAO · Genome.Blockchain · Metaverse DAO · Robotics DAO · Aerospace DAO · Solar DAO · InfoGurus